Rheumatoid Arthritis

Scroll through the slides for a review of the many options available to help reduce pain and improve function.

The ACTPen was approved on the basis of a pair of clinical trials presented at the 2018 American Society for Clinical Pharmacology & Therapeutics Annual Meeting.

Flares of rheumatoid arthritis have been linked to higher disease activity, lower quality of life, and increased radiographic progression.

Speaking ambitiously, determining the right tests and initial therapies for patients with rheumatoid arthritis could become optimized.

Belgian researchers sought to determine which patients are appropriate candidates for tapering biologics. In this article, we summarize their findings.

How will you respond to patients who ask about treating rheumatoid arthritis with cannabinoids?

What next when methotrexate monotherapy fails? The answer-and 4 more questions on RA treatment-can be found here.

Recent findings allay concerns about increased costs and rates of adverse events related to TTT strategies.

What’s new: biologic tapering, high-dose influenza vaccine, real-time patient input.

New data shows patients with rheumatoid arthritis do not change their current treatment to reach a “treat-to-target” goal for low disease activity.

A strategy to boost the immune response to vaccination in patients with seropositive rheumatoid arthritis.

Two recent studies address expectations and outcomes following knee and hip replacement in patients with rheumatoid arthritis.

Answer these 8 questions to test your knowledge of the latest RA research findings.

Patients with rheumatoid arthritis who had inadequate response to previous biologic disease-modifying antirheumatic drugs found greater pain relief when taking 2 mg or 4 mg of baricitinib compared with placebo.

The findings led the team to believe a focus on treatment strategy, rather than disease activity, is more indicative of aortic distensibility improvement.

Data from the SELECT-MONOTHERAPY trial in patients with rheumatoid arthritis show that upadacitinib improved outcomes in pain, physical function, health-related quality of life, and morning stiffness.

Obesity in patients with rheumatoid arthritis has been found to influence the effectiveness of JAKi inhibitor treatments.

Eric M. Ruderman, MD, addresses adverse events and toxicities in patients taking disease-modifying antirheumatic drugs (DMARDs).

Investigators assessed the risk of developing malignancies or serious infections with JAK inhibitors for RA treatment.

Patients with active rheumatoid arthritis who are cs/bDMARD-naïve may see a greater reduction in pain and improvement in physical function on baricitinib monotherapy compared with monotherapy of tocilizumab or adalimumab.

Seropositivity was strongly associated with ILD risk in this large prospective cohort study.

The following medications were decreased most frequently and also associated with the greatest impact in terms of reduction of annual cost: adalimumab, etanercept, and rituximab.

Five questions to test your knowledge of the prevalence, risk, and classification of RA.

The Mediterranean diet may reduce the risk of rheumatoid arthritis in seropositive men.

Rheumatoid arthritis and juvenile idiopathic arthritis put pregnant women at risk for preterm delivery.